288 related articles for article (PubMed ID: 19826477)
1. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.
Soh J; Okumura N; Lockwood WW; Yamamoto H; Shigematsu H; Zhang W; Chari R; Shames DS; Tang X; MacAulay C; Varella-Garcia M; Vooder T; Wistuba II; Lam S; Brekken R; Toyooka S; Minna JD; Lam WL; Gazdar AF
PLoS One; 2009 Oct; 4(10):e7464. PubMed ID: 19826477
[TBL] [Abstract][Full Text] [Related]
2. Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications.
Yu CC; Qiu W; Juang CS; Mansukhani MM; Halmos B; Su GH
Cancer Lett; 2017 Jan; 384():86-93. PubMed ID: 27725226
[TBL] [Abstract][Full Text] [Related]
3. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
Gandhi J; Zhang J; Xie Y; Soh J; Shigematsu H; Zhang W; Yamamoto H; Peyton M; Girard L; Lockwood WW; Lam WL; Varella-Garcia M; Minna JD; Gazdar AF
PLoS One; 2009; 4(2):e4576. PubMed ID: 19238210
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
5. KRAS mutant allele-specific imbalance in lung adenocarcinoma.
Chiosea SI; Sherer CK; Jelic T; Dacic S
Mod Pathol; 2011 Dec; 24(12):1571-7. PubMed ID: 21743433
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic activating mutations are associated with local copy gain.
Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
[TBL] [Abstract][Full Text] [Related]
7. Higher dosage of the epidermal growth factor receptor mutant allele in lung adenocarcinoma correlates with younger age, stage IV at presentation, and poorer survival.
Oakley GJ; Chiosea SI
J Thorac Oncol; 2011 Aug; 6(8):1407-12. PubMed ID: 21587084
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas.
Krasinskas AM; Moser AJ; Saka B; Adsay NV; Chiosea SI
Mod Pathol; 2013 Oct; 26(10):1346-54. PubMed ID: 23599154
[TBL] [Abstract][Full Text] [Related]
9. Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival.
Hartman DJ; Davison JM; Foxwell TJ; Nikiforova MN; Chiosea SI
Int J Cancer; 2012 Oct; 131(8):1810-7. PubMed ID: 22290300
[TBL] [Abstract][Full Text] [Related]
10. EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer.
Malapelle U; Vatrano S; Russo S; Bellevicine C; de Luca C; Sgariglia R; Rocco D; de Pietro L; Riccardi F; Gobbini E; Righi L; Troncone G
J Clin Pathol; 2015 Sep; 68(9):739-41. PubMed ID: 26047622
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.
Nomura M; Shigematsu H; Li L; Suzuki M; Takahashi T; Estess P; Siegelman M; Feng Z; Kato H; Marchetti A; Shay JW; Spitz MR; Wistuba II; Minna JD; Gazdar AF
PLoS Med; 2007 Apr; 4(4):e125. PubMed ID: 17455987
[TBL] [Abstract][Full Text] [Related]
12. Recurrent copy number gains drive PKCι expression and PKCι-dependent oncogenic signaling in human cancers.
Liu Y; Justilien V; Fields AP; Murray NR
Adv Biol Regul; 2020 Dec; 78():100754. PubMed ID: 32992230
[TBL] [Abstract][Full Text] [Related]
13. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer.
Uchiyama M; Usami N; Kondo M; Mori S; Ito M; Ito G; Yoshioka H; Imaizumi M; Ueda Y; Takahashi M; Minna JD; Shimokata K; Sekido Y
Int J Cancer; 2003 Dec; 107(6):962-9. PubMed ID: 14601056
[TBL] [Abstract][Full Text] [Related]
15. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
[TBL] [Abstract][Full Text] [Related]
16.
Chung WJ; Daemen A; Cheng JH; Long JE; Cooper JE; Wang BE; Tran C; Singh M; Gnad F; Modrusan Z; Foreman O; Junttila MR
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10947-E10955. PubMed ID: 29203670
[No Abstract] [Full Text] [Related]
17. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
[TBL] [Abstract][Full Text] [Related]
18. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
[TBL] [Abstract][Full Text] [Related]
19. The chromosome 3q26 OncCassette: A multigenic driver of human cancer.
Fields AP; Justilien V; Murray NR
Adv Biol Regul; 2016 Jan; 60():47-63. PubMed ID: 26754874
[TBL] [Abstract][Full Text] [Related]
20. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.
Kerr EM; Gaude E; Turrell FK; Frezza C; Martins CP
Nature; 2016 Mar; 531(7592):110-3. PubMed ID: 26909577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
